| scholarly article | Q13442814 |
| P50 | author | Daniel P Jones | Q63625394 |
| P2093 | author name string | Jyoti Patel | |
| P2860 | cites work | Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association | Q22241929 |
| ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) | Q22242892 | ||
| Prophylactic corticosteroids for cardiopulmonary bypass in adults | Q24234553 | ||
| Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials | Q24546221 | ||
| Atherosclerosis — An Inflammatory Disease | Q26776972 | ||
| Attenuating the Systemic Inflammatory Response to Adult Cardiopulmonary Bypass: A Critical Review of the Evidence Base | Q26781711 | ||
| Inflammation, oxidative stress and postoperative atrial fibrillation in cardiac surgery | Q26849245 | ||
| Inflammation and C-reactive protein in atrial fibrillation: cause or effect? | Q26865381 | ||
| Association of monocyte subset counts with coronary fibrous cap thickness in patients with unstable angina pectoris | Q42975955 | ||
| Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis | Q43049221 | ||
| Effect of a neutrophil elastase inhibitor on acute lung injury after cardiopulmonary bypass | Q43114472 | ||
| The effects of METhotrexate therapy on the physical capacity of patients with ISchemic heart failure: a randomized double-blind, placebo-controlled trial (METIS trial). | Q43234440 | ||
| Reduced expression of systemic proinflammatory and myocardial biomarkers after off-pump versus on-pump coronary artery bypass surgery: a prospective randomized study. | Q43271117 | ||
| Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial | Q43777913 | ||
| The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. | Q43925988 | ||
| Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). | Q44244528 | ||
| Significance of acute-phase inflammatory reactants as an indicator of prognosis after acute myocardial infarction: which is the most useful predictor? | Q44578681 | ||
| Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice | Q44680905 | ||
| Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. | Q44938264 | ||
| Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). | Q44956453 | ||
| Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis | Q45166918 | ||
| C-reactive protein levels and outcomes after statin therapy | Q45213511 | ||
| Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice | Q45240037 | ||
| Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST-elevation acute coronary syndromes. | Q46450501 | ||
| Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial | Q46576382 | ||
| C-reactive protein in heart failure: prognostic value and the effect of valsartan | Q46676009 | ||
| Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study | Q46814878 | ||
| Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis | Q46897070 | ||
| Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu | Q47849023 | ||
| Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy | Q47860383 | ||
| Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). | Q47945239 | ||
| Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials | Q48458509 | ||
| Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities | Q48501090 | ||
| Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study | Q28193363 | ||
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| The pathogenesis of atherosclerosis: a perspective for the 1990s | Q29547827 | ||
| Cardiovascular disease risk factors: epidemiology and risk assessment. | Q30384873 | ||
| The pathogenesis of atherosclerosis (first of two parts) | Q33492794 | ||
| C-reactive Protein as a Predictor of Adverse outcome in Patients with Acute Coronary Syndrome | Q34032614 | ||
| Anti-inflammatory therapies for cardiovascular disease | Q34137872 | ||
| Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. | Q34515828 | ||
| Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to Elimin | Q34649311 | ||
| Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial | Q34817061 | ||
| Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial | Q34949268 | ||
| Meta-analysis of corticosteroid treatment in acute myocardial infarction | Q35114495 | ||
| The development of myocardial fibrosis in transgenic mice with targeted overexpression of tumor necrosis factor requires mast cell-fibroblast interactions | Q35552846 | ||
| Cytokine-induced modulation of cardiac function | Q35980361 | ||
| Intertwining of thrombosis and inflammation in atherosclerosis | Q36667645 | ||
| Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. | Q36816882 | ||
| Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis | Q36942534 | ||
| Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology | Q37090971 | ||
| Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. | Q37209164 | ||
| Macrophage migration inhibitory factor for the early prediction of infarct size. | Q37328708 | ||
| Pregnancy associated plasma protein-A (PAPP-A) as an early marker for the diagnosis of acute coronary syndrome | Q37386914 | ||
| Coronary stents: looking forward | Q37783396 | ||
| The evolving role of inflammatory biomarkers in risk assessment after stent implantation | Q37810669 | ||
| Restenosis after PCI. Part 2: prevention and therapy | Q37944416 | ||
| Positioning of inflammatory biomarkers in the heart failure landscape | Q38105986 | ||
| The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities. | Q38144845 | ||
| Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction | Q38188327 | ||
| Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis | Q38377634 | ||
| Innate immunity and the failing heart: the cytokine hypothesis revisited | Q38393039 | ||
| Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial | Q38400764 | ||
| Systemic inflammatory response following acute myocardial infarction | Q38531965 | ||
| Chronic Heart Failure and Inflammation: What Do We Really Know? | Q38875783 | ||
| Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). | Q39405703 | ||
| CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography | Q39549158 | ||
| Prognostic value of high-sensitivity C-reactive protein in a population of post-acute coronary syndrome patients receiving optimal medical treatment | Q39709793 | ||
| CD14CD16 monocyte subset levels in heart failure patients. | Q41861504 | ||
| Inhibition of systemic inflammatory response with sodium nitroprusside in open heart surgery. | Q51310844 | ||
| Association of monocyte subsets with vulnerability characteristics of coronary plaques as assessed by 64-slice multidetector computed tomography in patients with stable angina pectoris. | Q53280246 | ||
| Perioperative Rosuvastatin in Cardiac Surgery. | Q54604760 | ||
| Third Universal Definition of Myocardial Infarction | Q56535247 | ||
| Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease | Q57243317 | ||
| Ccr5 But Not Ccr1 Deficiency Reduces Development of Diet-Induced Atherosclerosis in Mice | Q61386204 | ||
| Elevated circulating levels of tumor necrosis factor in severe chronic heart failure | Q68524243 | ||
| A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy | Q69544225 | ||
| In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia | Q74027568 | ||
| Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor | Q74364510 | ||
| Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats | Q74522770 | ||
| Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators | Q78017116 | ||
| Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial | Q79533790 | ||
| Antirheumatic drug use and the risk of acute myocardial infarction | Q80016233 | ||
| [The organ effects of systemic inflammation response activated during open heart surgery and current treatment methods] | Q80541808 | ||
| Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction | Q80841277 | ||
| The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction | Q83164621 | ||
| Monocyte heterogeneity in obesity and subclinical atherosclerosis | Q84419725 | ||
| Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) | Q85063666 | ||
| CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease | Q85189304 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P577 | publication date | 2018-11-16 | |
| P1433 | published in | Biology | Q17509951 |
| P1476 | title | Therapeutic Approaches Targeting Inflammation in Cardiovascular Disorders | |
| P478 | volume | 7 |
Search more.